Gemcitabine adjuvant therapy for resected pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 3, 2015, Pages 322-325

  Yu, Zhong ^a   Zhong, Wa ^a   Tan, Zhi Ming ^a   Wang, Ling Yun ^a   Yuan, Yu Hong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 fluorouracil; adjuvant therapy; gemcitabine; pancreatic cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ADJUVANT THERAPY; AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; PANCREATIC NEOPLASMS; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84930758601     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182a46782     Document Type: Review

References (25)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for m1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007; 14:118-127.
4. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the national cancer database. J Am Coll Surg. 1999;189:1-7.
5. Loos M, Kleeff J, Friess H, et al. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci. 2008;1138:169-180.
6. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
7. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20: 3270-3275.
8. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor bay 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2003;21:3296-3302.
9. Herreros-Villanueva M, Hijona E, Cosme A, et al. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol. 2012;18:1565-1572.
10. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
11. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230:776-782; discussion 782-4.
12. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
13. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319-1326.
14. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
15. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (amf) following radical resection of carcinoma of the pancreas and papilla of vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993; 29A:698-703.
16. Lygidakis NJ, Berberabe AE, Spentzouris N, et al. A prospective randomized study using adjuvant locoregional chemoimmunother-apy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology. 1998;45:2376-2381.
17. Kosuge T, Kiuchi T, Mukai K, et al. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159-165.
18. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Ccancer. 2009;101:908-915.
19. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073-1081.
20. Neuhaus P, Riess H, Post S, et al. Conko-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol. 2009;26:LBA4505.
21. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology. 2007;72:314-321.
22. Sultana A, Cox T, Ghaneh P, et al. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65-88.
23. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med. 2009;13:1221-1227.
24. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009; 6:412-422.
25. Picozzi VJ, Pisters PW, Vickers SM, et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008;12:657-661.